热门资讯> 正文

Rapport Therapeutics将2.5亿美元的股票定价为每股26美元

2025-09-10 15:30

Rapport Therapeutics (NASDAQ:RAPP) priced an underwritten public offering of 9.62M shares at a public offering price of $26.00 per share.
The underwriters have a 30-day option to purchase up to an additional 1.44M shares.
The gross proceeds from the offering are expected to be ~$250M.
The offering is expected to close on or about September 11, 2025.

More on Rapport Therapeutics

Rapport: Surging On Phase 2 Study Win - Full Approval Unlikely Before 2028
Biggest stock movers Monday: RAPP, MCRB, SATS, QS, SMMT and more
Rapport Therapeutics soars 23% on release of phase 2 data for seizure asset
Seeking Alpha’s Quant Rating on Rapport Therapeutics
Historical earnings data for Rapport Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。